Literature DB >> 3526354

Steady-state level and turnover rate of the tripeptide Tyr-Gly-Gly as indexes of striatal enkephalin release in vivo and their reduction during pentobarbital anesthesia.

C Llorens-Cortes, C Gros, J C Schwartz.   

Abstract

Tyr-Gly-Gly (YGG) was recently shown to be an extraneuronal metabolite of opioid peptides derived from proenkephalin A, formed in brain by the action of "enkephalinase" (membrane metalloendopeptidase, EC 3.4.24.11) and degraded by aminopeptidases. The dynamic state of YGG in mouse striatum was studied by evaluating the changes in its level elicited by inhibitors of these peptidases. Inhibition of YGG synthesis by Thiorphan or acetorphan reduced YGG levels with a t1/2 (mean +/- SEM) of 12 +/- 2 min, indicating an apparent turnover rate (mean +/- SEM) of 18 +/- 2 pmol/mg of protein per hr. An apparent turnover rate of 18 +/- 2 pmol/mg of protein per hr was derived from the rate of YGG accumulation elicited by the aminopeptidase inhibitor bestatin. In addition, accumulation of Tyr-Gly-Gly-Phe-Met (YGGFM) in an extrasynaptosomal fraction after blockade of its degradation by Thiorphan and bestatin occurred at a rate of 18 +/- 3 pmol/mg of protein per hr, which is likely to reflect the rate of enkephalin release in vivo. Hence, the three series of data suggest that striatal enkephalins rapidly turn over--e.g., with a t1/2 in the 1-hr range. Pentobarbital anesthesia reduced by about 60% the rate of YGG accumulation elicited by bestatin and the extrasynaptosomal YGGFM accumulation elicited by Thiorphan and bestatin. This suggests that the activity of striatal enkephalin neurons is depressed during anesthesia. Pentobarbital (and chloral hydrate) did not affect the steady-state level of YGGFM but rapidly reduced that of YGG. Hence, the steady-state levels of YGG seem a reliable index of changes in enkephalin release, and measuring levels of characteristic fragments might therefore provide a general means of evaluating neuropeptide release in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3526354      PMCID: PMC386473          DOI: 10.1073/pnas.83.16.6226

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse.

Authors:  T J HALEY; W G MCCORMICK
Journal:  Br J Pharmacol Chemother       Date:  1957-03

2.  Radioimmunoassay of methionine- and leucine-enkephalins in regions of rat brain and comparison with endorphins estimated by a radioreceptor assay.

Authors:  C Gros; P Pradelles; C Rouget; O Bepoldin; F Dray; M C Fournie-Zaluski; B P Roques; H Pollard; C Llorens-Cortes; J C Schwartz
Journal:  J Neurochem       Date:  1978-07       Impact factor: 5.372

3.  The adsorption of enkephalin to porous polystyrene beads: a simple assay for enkephalin hydrolysis.

Authors:  Z Vogel; M Altstein
Journal:  FEBS Lett       Date:  1977-08-15       Impact factor: 4.124

4.  Barbiturates and meprobamate: decreases in cathecholamine turnover of central dopamine and noradrenaline neuronal systems and the influence of immobilization stress.

Authors:  P Lidbrink; H Corrodi; K Fuxe; L Olson
Journal:  Brain Res       Date:  1972-10-27       Impact factor: 3.252

5.  Turnover of histamine in rat brain and its decrease under barbiturate anesthesia.

Authors:  H Pollard; S Bischoff; J C Schwartz
Journal:  J Pharmacol Exp Ther       Date:  1974-07       Impact factor: 4.030

6.  Rat brain enkephalins: distribution and biosynthesis.

Authors:  H Y Yang; J S Hong; W Fratta; E Costa
Journal:  Adv Biochem Psychopharmacol       Date:  1978

7.  The effect of some psychoactive drugs on central monoamine neurons.

Authors:  H Corrodi; K Fuxe; T Hökfelt
Journal:  Eur J Pharmacol       Date:  1967-09       Impact factor: 4.432

Review 8.  Measurements of monoamine synthesis and turnover with special reference to 5-hydroxytryptamine.

Authors:  A Carlsson
Journal:  Adv Biochem Psychopharmacol       Date:  1974

9.  Incorporation of labelled amino acids into the enkephalins.

Authors:  R P Sosa; A T McKnight; J Hughes; H W Kosterlitz
Journal:  FEBS Lett       Date:  1977-12-01       Impact factor: 4.124

10.  Application of steady state kinetics to the estimation of synthesis rate and turnover time of tissue catecholamines.

Authors:  B B Brodie; E Costa; A Dlabac; N H Neff; H H Smookler
Journal:  J Pharmacol Exp Ther       Date:  1966-12       Impact factor: 4.030

View more
  4 in total

1.  Aminopeptidase A inhibitors as potential central antihypertensive agents.

Authors:  A Reaux; M C Fournie-Zaluski; C David; S Zini; B P Roques; P Corvol; C Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 2.  The double-edged sword of gut bacteria in celiac disease and implications for therapeutic potential.

Authors:  Heather J Galipeau; Elena F Verdu
Journal:  Mucosal Immunol       Date:  2022-01-14       Impact factor: 7.313

3.  A serine peptidase responsible for the inactivation of endogenous cholecystokinin in brain.

Authors:  C Rose; A Camus; J C Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

4.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.